



PRESS RELEASE

Lund, 8 March 2011

## **STRENGTHENING THE ORGANISATION IN SWEDEN AND JAPAN**

**EXINI Diagnostics AB (publ) is strengthening the organisation through Klas Themner as its new COO in Lund, and through Thomas Jonsson, who is in charge of continued canvassing of the Asian market. Through the Swedish Embassy and Medicon Valley Alliance, Thomas has recently advised and assisted EXINI in the negotiations with FUJIFILM Pharma.**

During the winter EXINI achieved an international breakthrough in Japan, and during 2011 the business will move from a negative to a positive cash flow. The contract with FUJIFILM will also act as a strong reference in forthcoming discussions with manufacturers (OEMs) and end customers (hospitals). EXINI sees a need to strengthen its organisation, both at head office in Lund and on the Asian market.

As from March Klas Themner, PhD will be joining as EXINI's COO. The company is facing a phase of expansion, and Klas is strengthening EXINI by focusing on organisational, financial and legal issues. Klas has a background of 10 years' equivalent work in the listed medical-technology companies ContextVision and SharpView.

Thomas Jonsson, BA has acted as an advisor for EXINI in the negotiations in Japan on behalf of Medicon Valley Alliance. Thomas has over 15 years' commercial experience of the Japanese pharmaceutical and medical-technology market from Pfizer and Astra, and speaks fluent Japanese. Thomas will initially be working part-time for EXINI, concentrating on Japan, and will be focusing on creating new business and simultaneously being the contact for existing customers.

"By strengthening the organisation both domestically and in Asia, we are paving the way for even more active canvassing of the market," says Magnus Aurell, EXINI's CEO, and continues: "Klas will create stability and security for current business, whilst I will be able to focus on driving EXINI forwards with new business contacts. With his wide-ranging contact network, Thomas will be an important resource on the Asian market, and will be readily at hand for our customers – which will benefit new and existing business relations in Asia."

During the period 2-17 March 2011 EXINI is carrying out a guaranteed preferential share issue. The subscription price is set at SEK 0.60.

Trading in subscription rights will take place during the period 2-11 March 2011.

The prospectus can be downloaded from [www.aktietorget.se](http://www.aktietorget.se) and [www.exini.com](http://www.exini.com)

### **For further information please contact:**

Magnus Aurell, CEO

Tel.: +46 (0)46-286 54 25

E-mail: [magnus.aurell@exini.com](mailto:magnus.aurell@exini.com)

### **About EXINI Diagnostics AB (publ)**

EXINI Diagnostics AB (publ) offers advanced solutions for support in medical decision-making to hospitals worldwide. The system is based on advanced image analysis through artificial intelligence, and can independently interpret X-ray images and make diagnostic proposals. The system is used in this way as decision-making support for the diagnosing physician. EXINI is working on products for diagnosis of some of the most widespread diseases, e.g. coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Prof. Lars Edenbrandt, and now has 12 employees. EXINI is listed on AktieTorget, and has about 250 shareholders. The main owner is Bo Håkansson.